Drug Trial Radar · NCT03740165
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,367
Actual
Start
Dec 18, 2018
Primary completion
Aug 26, 2024
Study completion Apr 14, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- European Network of Gynaecological Oncological Trial Groups (ENGOT); Gynecologic Oncology Group
- First posted
- Nov 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel\* PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary peritoneal cancer. The primary study hypotheses are that the combination of pembrolizumab plus carboplatin/paclitaxel\* followed by continued pembrolizumab and maintenance olaparib is superior to carboplatin/paclitaxel alone with respect to Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in participants with programmed death-ligand 1 (PD-L1) positive tumors (Combined Positive Score \[CPS\]≥10) and in all participants, and that the combination of pembrolizumab plus carboplatin/paclitaxel followed by continued pembrolizumab is superior to carboplatin/paclitaxel alone with respect to PFS per RECIST 1.1 in participants with PD-L1 positive tumors (CPS≥10) and in all participants.
Conditions
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Neoplasms
Interventions
PembrolizumabBiological
IV infusion
Placebo for pembrolizumabDrug
IV infusion
CarboplatinDrug
IV infusion
PaclitaxelDrug
IV infusion
OlaparibDrug
Oral tablet
Placebo for olaparibDrug
Oral tablet
BevacizumabBiological
IV infusion
DocetaxelDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS]≥10)Time frame: Up to approximately 67 months
- PFS Per RECIST 1.1 as Assessed by the Investigator in All ParticipantsTime frame: Up to approximately 67 months
Locations
227 sites in 22 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham (UAB) ( Site 0036)
Birmingham, Alabama
University of Arizona Cancer Center ( Site 0074)
Tucson, Arizona
Disney Family Cancer Center ( Site 0042)
Burbank, California
Kaiser Permanente Oncology Clinical Trial -Oakland ( Site 0077)
Oakland, California
Kaiser Permanente Oncology Clinical Trials-Roseville ( Site 0084)
Roseville, California
Kaiser Permanente Oncology Clinical Trials-Sacramento ( Site 0083)
Sacramento, California
Kaiser Permanente Oncology Clinical Trial - San Francisco ( Site 0078)
San Francisco, California
Kaiser Permanente Oncology Clinical Trial - Santa Clara ( Site 0079)
Santa Clara, California
Kaiser Permanente N. CA Regional Oncology Clinical Trials ( Site 0008)
Vallejo, California
Kaiser Permanente Oncology Clinical Trial - Walnut Creek ( Site 0080)
Walnut Creek, California
Smilow Cancer Center at Yale-New Haven ( Site 0057)
New Haven, Connecticut
Sarasota Memorial Hospital ( Site 0023)
Sarasota, Florida
Emory School of Medicine ( Site 0053)
Atlanta, Georgia
Northeast Georgia Medical Center ( Site 0029)
Gainesville, Georgia
Memorial Health University Medical Center ( Site 0011)
Savannah, Georgia
Rush University Medical Center ( Site 0019)
Chicago, Illinois
University of Chicago ( Site 0049)
Chicago, Illinois
Dr. Sudarshan K. Sharma, LTD ( Site 0061)
Hinsdale, Illinois
Saint Vincent Hospital and Health Center ( Site 0012)
Indianapolis, Indiana
University of Iowa Hospital and Clinics ( Site 0005)
Iowa City, Iowa
University of Kentucky ( Site 0045)
Lexington, Kentucky
Weinberg Cancer Institute at Franklin Square ( Site 0035)
Baltimore, Maryland
Saint Dominic - Jackson Memorial Hospital ( Site 0072)
Jackson, Mississippi
Washington University - School of Medicine ( Site 0062)
St Louis, Missouri
Nebraska Methodist Hospital ( Site 0063)
Omaha, Nebraska
Dartmouth Hitchcock Medical Center ( Site 0024)
Lebanon, New Hampshire
MD Anderson Cancer Center at Cooper ( Site 0067)
Camden, New Jersey
Holy Name Medical Center ( Site 0037)
Teaneck, New Jersey
Northwell Health- Monter Cancer Center ( Site 0075)
Lake Success, New York
Sanford Roger Maris Cancer Center ( Site 0082)
Fargo, North Dakota
Miami Valley Hospital [Dayton, OH] ( Site 0073)
Centerville, Ohio
Oncology/Hematology Care Clinical Trials, LLC ( Site 8001)
Cincinnati, Ohio
The Bing Cancer Center ( Site 0044)
Columbus, Ohio
OSU Wexner Medical Center ( Site 0076)
Hilliard, Ohio
Women and Infants Hospital [Providence, RI] ( Site 0039)
Providence, Rhode Island
Sanford Gynecology Oncology ( Site 0004)
Sioux Falls, South Dakota
Texas Oncology, P.A. - Bedford ( Site 8005)
Bedford, Texas
Texas Oncology-Dallas Presbyterian Hospital ( Site 8004)
Dallas, Texas
Parkland Hospital ( Site 0081)
Dallas, Texas
UT Southwestern Medical Center ( Site 0046)
Dallas, Texas
Showing 40 of 227 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.